Prurigo Nodularis PaTient-Reported BurdEn of SicKness (PN TREK): A Cross-Sectional Survey of Patient-Reported Burden of Disease in Patients with PN from the US
In patients with PN, severe itching is associated with an increased symptom burden, greater disease impact, along with reduced satisfaction with non-biologic treatments. Additionally, the number of nodules alone may not adequately describe disease severity in patients with PN.
Authors
- Donia Bahloul (ORCID: https://orcid.org/0009-0008-9887-8159)
- Marisa Payan
- Ryan B. Thomas (ORCID: https://orcid.org/0000-0002-1141-2073)
- Joseph Zahn
- Bengisu Ozarslan (ORCID: https://orcid.org/0000-0001-9521-0147)
- Shawn G. Kwatra (ORCID: https://orcid.org/0000-0003-3736-1515)
- Min Yang (ORCID: https://orcid.org/0000-0002-3827-5961)
- Bruno Martins (ORCID: https://orcid.org/0000-0001-7484-1011)
- Abigail Zion
- Jingyi Liu (ORCID: https://orcid.org/0000-0001-7360-0267)
Institutions
- University of Maryland, Baltimore (US)
- Regeneron (United States) (US)
- Sanofi (France) (FR)
- Sanofi (United States) (US)
- Sanofi (Turkey) (TR)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1007/s12325-025-03217-4
- Citations
- 3
- Primary Topic
- Medicine and Dermatology Studies History
- Type
- article
- Field-Weighted Citation Impact
- 6.01
Funders
- Sanofi
- Regeneron Pharmaceuticals